Review Article

Ginsenoside Rb2: A review of pharmacokinetics and pharmacological effects

Longxing Miao a, Yijun Yang b, Zhongwen Li b, Zengjun Fang c, Yongqing Zhang a, d, **, Chun-chao Han a, d, *

a School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
b Department of Pharmacy, Shandong Medical College, Jinan, China
c The Second Hospital, Cheeloo College of Medicine, Shandong University, China
d Shandong Provincial Collaborative Innovation Center for Quality Control and Construction of the Whole Industrial Chain of Traditional Chinese Medicine, Jinan, Shandong, China

ABSTRACT

Ginsenoside Rb2 is an active protopanaxadiol-type saponin, widely existing in the stem and leave of ginseng. Rb2 has recently been the focus of studies for pharmaceutical properties. This paper provides an overview of the preclinical and clinical pharmacokinetics for Rb2, which exhibit poor absorption, rapid tissue distribution and slow excretion through urine. Pharmacological studies indicate a beneficial role of Rb2 in the prevention and treatment of diabetes, obesity, tumor, photoaging, virus infection and cardiovascular problems. The underlying mechanism is involved in an inhibition of oxidative stress, ROS generation, inflammation and apoptosis via regulation of various cellular signaling pathways and molecules, including AKT/SHP, MAPK, EGFR/SOX2, TGF-β1/Smad, SIRT1, GPR120/AMPK/HO-1 and NF-κB. This work would provide a new insight into the understanding and application of Rb2. However, its therapeutic effects have not been clinically evaluated. Further studies should be aimed at the clinical treatment of Rb2.

© 2021 The Korean Society of Ginseng. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Ginseng is a perennial plant belonging to the Araliaceae family, and it has been recorded and used as a medicine herb for thousands of years in East Asia [1]. To date, 13 species of ginseng have been identified, in which Panax ginseng Meyer (Asian ginseng) and Panax quinquefolius L (American ginseng) are the most well-known as function food [2,3]. Ginsenosides are a group of triterpene saponins and exhibit comprehensive bioactivities [4]. Nearly 150 ginsenosides have been isolated from the root, stem, fruits, leaves and flowers of ginseng [5]. Based on the chemical structure, ginsenosides are mainly divided into protopanaxadiol (PPD), protopanaxatriol (PPT), oleanolic acid type and ocotillol type [4].

Ginsenoside Rb2 is an active PPD-type saponin and widely distributed in different kinds and parts of ginseng. It is relatively rich in P. ginseng (0.073–0.421%) and Panax quinquefolius (0.194–0.219%), but in Panax japonicus and Panax notoginseng did not nearly exist [4]. In the ginseng, Rb2 is primarily concentrated in the stems, leaves and berries [5]. The molecular formula and structure of Rb2 is shown in Fig. 1, whose major differences from other PPDs are the sugar moiety in side chains [6]. Recently, pharmacokinetic properties of Rb2 in animal models have been extensively studied, but only a few relevant investigations in humans are reported. And many pharmacological studies have showed the comprehensive effects of Rb2 against diabetes, obesity, tumor, photoaging, virus infection and cardiovascular problems. To our knowledge, there is no published review to assess the pharmacological effects of Rb2 based on summarizing the current reliable evidence. Herein, this paper systematically summaries pharmacokinetic properties and pharmacological activities of Rb2.
and it would provide a theoretical basis for further pharmaceutical studies and clinical application.

2. Pharmacokinetics

Pharmacokinetics determines the drug concentrations at the target site, and is crucial to play pharmacological effects. However, there is little report about the relevant reviews of Rb2. Thus, we summarized most studies that investigated its pharmacokinetics (Tables 1 and 2).

2.1. Preclinical pharmacokinetics

Absorption, distribution, metabolism and excretion (ADME) are key factors that influence tissue drug concentrations over time [7]. Zhao et al. [8] compared the similarities and differences between pharmacokinetic behaviors of Rb2 via oral and intravenous administration in rats (50 and 10 mg/kg, respectively). The area under the plasma concentration-time curve (AUC) of Rb2 with two administration methods were 9.7 ± 3.2 and 20066.3 ± 283.0 mg h/L, respectively; maximum plasma concentrations (Cmax) were 0.4 ± 0.1 and 198.1 ± 27.9 mg/L respectively; the bioavailability of Rb2 was only 0.08%. These data indicated the oral absorption of Rb2 was extremely low.

Poor oral absorption was mainly attributed to low permeability of Rb2 in the intestine, due to its large molecular mass, high hydrogen-bonding capacity and high molecular flexibility [9]. It was verified by the Caco-2 cell assay in vitro, in which the membrane permeability of Rb2 was poor with the Papp of 2.8 × 10⁻⁷ cm/s [10]. Another factor was that Rb2 was susceptible to degrade or bio-transform under gastric acid or intestinal bacteria [11]. Rb2 could be transformed to minor ginsenosides, including Rd, F2, compound O, compound Y and compound K, by the intestinal microflora, which were hardly present in unprocessed ginseng [12]. These minor ginsenosides were readily permeated into the bloodstream, and may have a competitive absorption against Rb2 [13]. In addition, Rb2 was a low water-soluble ginsenoside, resulting in irregular and incomplete absorption in the body. These factors may limit the absorption and exposure of Rb2 in plasma.

In another study, a single dose of 10.4 mg/kg ShenMai injection, a traditional Chinese herbal medicine composed of ginseng extract and Ophiopogon radix, was injected to rats via tail vein [14]. The result showed Rb2 had a long half-life (t1/2) with 75.4 ± 47.3 h, and it could be still detected in serum at 96 h after administration, indicating that its elimination was slow in serum. The long elimination process may be partly attributed to high plasma protein binding [15]. The tissue distribution affected the efficacy and duration of action. Rb2 could spread into the heart, liver, spleen, lung and kidney at 5 min after dosing, and the highest concentrations were in the lung and kidney. In addition, Rb2 could penetrate through the blood-brain barrier and rapidly transport into the brain. It was worth noting that Rb2 had a long-term accumulation risk in the kidney and brain. The excretion profile was determined by detecting the concentration of Rb2 in urine and feces. The results indicated that Rb2 was only excreted into urine and was not found in feces. The accumulating concentration of Rb2 in urine was low with 21.3 ± 8.5 ng from 0 to 96 h, and it was still detected in urine until 96 h after administration. It was showed that Rb2 excretion was slow and relatively uniform, which was consistent with its slow elimination in plasma and tissue [14].

2.2. Herb-drug interaction

The reported cases of herb-drug interactions are rapidly increasing, and influence the concentration of drugs within the plasma or tissue [15]. Rb2 has been identified as a P-gp substrate, and drug-mediated alteration in P-gp activity had an influence on the exposure and disposition of Rb2 [16]. In vitro, verapamil, a P-gp inhibitor, caused a significant uptake of Rb2 in L-MDR1 cells. Yan et al. [17]described that in Caco-2 and L-MDR1 cells, Schisandra Lignanus (SLE) enhanced the exposure and declined of efflux ration of Rb2 through inhibiting the activity and expression of P-gp. In

![Fig. 1. Chemical structure of Rb2: 3-O-[β-D-Glucopyranosyl-(1→2)-β-D- glucopyranosyl]-20-O-[α-L-arabinopyranosyl-(1→6)-b-D-glucopyranosyl]-20(S)-protopanaxadiol.](image-url)

### Table 1

| Subject | Compound | Dose | Method | Cmax (ng/mL) | Tmax (h) | AUC (ng h/mL) | T1/2 (h) | Ref. |
|---------|----------|------|--------|-------------|---------|--------------|----------|-----|
| SD rats | Rb2      | 50 mg/kg | gavage | 400 ± 100  | 4.8 ± 3.5 | 970 ± 320  | 23.1 ± 3.7 | [8] |
| SD rats | Rb2      | 10 mg/kg | i.v.   | 19810 ± 27900 | 0.083 | 20060 ± 28309 | 15.4 ± 3.7 | [8] |
| SD rats | ShenMai  | 10.4 mg/kg | i.v. | NA | NA | 1,283,136 | 75.4 ± 47.3 | [14] |
| SD rats | RGE      | 1.5 g/kg for 7 d | gavage | 10.0 ± 1.0 | 3.3 ± 1.2 | 282.8 ± 58.9 | 30.2 ± 5.2 | [15] |
| SD rats | GE       | 1.5 g/kg for 15 d | gavage | 8.8 ± 3.6 | 3.0 ± 3.1 | 317.0 ± 145.9 | 68.7 ± 26.9 | [15] |
| SD rats | GE       | 120 mg/kg | gavage | 330.4 ± 70.8 | 7.0 ± 2.0 | 10224 ± 1706 | 19.4 ± 2.9 | [18] |
| SD rats | GE + SLE | 120 ± 500 mg/kg | gavage | 540.9 ± 45.0 | 9.5 ± 3.0 | 22310 ± 5273 | 19.0 ± 1.8 | [18] |
| SD rats | PQ extract | 0.54 mg/kg | gavage | 160.1 ± 18.8 | 7.7 ± 0.8 | 1229.9 ± 99.6 | 13.3 ± 1.6 | [16] |
| SD rats | PQ-AG extract | 0.54 mg/kg | gavage | 264.1 ± 24.5 | 7.7 ± 0.8 | 1229.9 ± 99.6 | 15.6 ± 5.2 | [16] |
| SD rats | Shen-Fu  | 4.75 g/kg | gavage | 59.7 ± 15.6 | 28.0 ± 6.2 | 31677 ± 7009 | 19.7 ± 3.2 | [68] |
| SD rats | Ginseng berry extract | 600 mg/kg | gavage | 395.0 ± 285.0 | 10.0 ± 2.0 | 376 ± 214 | 15.9 ± 1.4 | [69] |
| SD rats | RGE      | 4 g/kg | i.v. | 116.6 ± 8.6 | 7.7 ± 0.8 | 3895.6 ± 6854 | 19.3 ± 6.8 | [70] |
| SD rats | Shenfu injection | 5.0 mL/kg | i.v. | NA | NA | 44.4 ± 20.2 | 35.6 ± 30.7 | [71] |
| SD rats | Weifuchun tablets | 0.9 g/kg | gavage | 263.3 ± 51.1 | 4.6 | 1686.4 ± 3046 | 2.563 ± 0.78 | [72] |
| Wistar rats | YiQiPuMai injection | 5 mL/kg | i.v. | 16290 ± 2150 | NA | 2421000 ± 46996 | 26.4 ± 1.2 | [73] |
| SD rats | RGE      | 100 mg/kg | i.v. | 10.4 ± 1.2 | 1.5 ± 0.2 | 89.6 ± 9.3 | 6.5 ± 1.5 | [74] |

AG Acorus gramineus; AUC, area under the plasma concentration-time curve; Cmax, maximum drug concentration; GE, ginseng extract; i.v. intravenous injection; MRT, mean residence time; NA no available; p.o. oral administration; PQ Panax quinquefolius; RGE, red ginseng extract; SD, Sprague Dawley; Tmax, time of maximum concentration; T1/2, half-life.
rats, single administration of ginseng extract and SLE increased AUC of Rb2 for 2.18-fold from 1055.1 ± 1728 to 23198 ± 5566 ng h/mL and Cmax for 1.63-fold from 330.46 ± 70.86 to 540.94 ± 45.03 ng/mL [18]. Tmax and T1/2 have not changed with the absence and presence of SLE. Multiple administration (for 10 continuous days) of SLE could significantly enhance the exposure of Rb2. These results indicated that SLE could enhance the exposure of Rb2 and change its pharmacokinetic properties as an inhibitor of P-gp. On the contrary, ginsenoside Rs2 had little inhibitory effect on P-gp in vitro, but its metabolites (compound k and 25-OH-PPD) could increase the intracellular accumulation of rhodamine 123 (a typical P-gp substrate). It indicated that oral administration of Rb2 may enhance the absorption of P-gp substrate drugs, due to it metabolized to compound K25-OH-PPD and other metabolites by the intestinal bacteria [19].

Organic anion transporting polypeptide (OATP/Oatp) transporters are responsible for the uptake of various drugs in the liver, and many clinical herb-drug interactions are caused due to OATP inhibited. In the HEK293 cells overexpressing drug transporters, Rb2 demonstrated high inhibitory on OATP1B3 and OATP1B1 with the IC50 of 1.76 and 47.6 μM, respectively. But in rats, Rb2 had limited change on the pharmacokinetics of valsartan, an OATP substrate, following repeated oral administration of ginseng products. The lack of in vivo herb-drug interaction between Rb2 and OATP substrates could be attributed to the low plasma concentration and hepatic distribution of Rb2, which is far from the IC50 required for inhibiting OATP activity [20].

Some studies have attempted to evaluate the herb-drug interaction of ginseng extract and ginsenosides on cytochrome P450 (CYP). THOMAS et al. [21] reported that in vitro Panax ginseng extract (GT15) decreased human recombinant CYP1A1, CYP1A2 and CYP1B1 activities, but individual Rb2 (0.66 μg/mL), equivalent to that found in an inhibitory concentration of GT15, did not affect their activities. Rb2 at a high concentration of 50 μg/mL could reduce CYP1A1, CYP1A2 and CYP1B1 activities. Other studies reported that Rb2 exhibited very weak inhibitory activity on CYP3A4, CYP2D6, CYP2C19 and CYP2C9 enzymes in vitro [22–24]. These in vitro data indicated that Rb2 had negligible effects on CYP enzymes, and it was predicted to hardly alter the metabolism of drugs whose elimination is via these P450 isoforms in vivo [25].

Based on this data generated above, Rb2 was thought as a substrate of these drug transporters and CYP enzymes. We should focus on the PK alternation of Rb2 due to Rb2-drug interaction. However, Rb2 had a tiny impact on the metabolism of drugs via P-gp, OATP and P450 in vivo, partly attributed to its low plasma concentration that hardly regulated these drug transports and enzymes.

### 2.3. Clinical pharmacokinetics

The clinical pharmacokinetics of Rb2, mostly as part of whole ginseng extract, was investigated. One paper compared the pharmacokinetics and tolerability of Rb2 after single and repeated administration of red ginseng extract (containing 11.4 ± 0.6 mg Rb2) for 15 days in healthy volunteers [26]. The concentrations of Rb2 in plasma was stable over time, and had a long T1/2, 38.19 ± 20.33 h and 68.96 ± 26.92 h respectively. The other pharmacokinetic parameters with single dose or repeated dose were as follows: Cmax, 126.0 ± 0.39 and 8.83 ± 3.68 ng/mL, AUC (47.12 ± 16.40 and 316.96 ± 145.92 ng h/mL), Tmax (3.87 ± 2.47 and 3.02 ± 3.08 h). The study indicated that multiple-dose boosted the accumulation of Cmax and AUC, but it had little impact on Tmax and T1/2. These results indicated that Rb2 had poor absorption and long metabolism.

Another study reported a detection method of 13 ginsenosides in human plasma after two week-repeated administration of red ginseng extract (containing 10.4 ± 1.2 mg Rb2) [27]. The key pharmacokinetic parameters of Rb2 were close to the previous study: Cmax, T1/2, AUC and Tmax were 6.9 ± 2.3, 51.2 ± 22.7 ng/mL and 97.6 ± 36.5 h respectively. The study highlighted that the plasma concentration of Rb2 was stable for 4–10 h post dose, indicating stable absorption and slow elimination. The long T1/2 also confirmed that Rb2 had a slow excretion process.

These results indicated that the preliminary pharmacokinetic properties of Rb2 in human beings were stable and reproduced. Data in Tables 1 and 2 showed that the T1/2 values of Rb2 in humans were much shorter than in normal rats. The longer half-life of Rb2 was more prominent in humans than in rats. Cmax and AUC confirmed the poor exposure of Rb2 in two species. Such results demonstrated that Rb2 in humans had a slower absorption and longer elimination compared with rats. To make a stronger conclusion, more research including the administration of individual Rb2 and larger population size should be implemented.

In summary, Rb2 exhibits poor exposure and bioavailability in animals and humans, mainly related to poor permeability across intestinal mucosa, metabolism in the intestine, and low water-soluble. Low bioavailability greatly limits its efficacy and application, and more studies should be investigated to crack this obstacle.

### 3. Pharmacology of Rb2

#### 3.1. Anti-diabetes and its complications

Type 2 diabetes (T2DM) is a disease of metabolic disorder, clinically characterized by chronic hyperglycemia [28]. Insulin...
resistance (IR) is the major cause of T2DM, resulting in target cells not sensitive to insulin and blood glucose level increasing [29]. The remission of IR is a critical challenge to treat T2DM. Another important factor for the prevalence of T2DM is due to a huge increase in the population being obese or overweight [30,31]. Ginseng and ginsenoside Rb2 possess the abilities against hyperglycemic, obesity, IR and hyperlipidemia by regulating glycemic metabolism, body weight, insulin sensitivity as well as fat accumulation, which contribute to the treatment of diabetes and relevant complications.

Insulin resistance (IR) is a medical condition that the body fails to make use of insulin properly, leading to the increase of glucose level. In a study exploring the potent ability of Rb2 against IR in high fat diet-induced mice (DIO), the mice administrated with 40 mg/kg Rb2 for 10 days had lower blood glucose level and higher insulin sensitivity compared with the control group [32]. More Rb2 concentration, 40 mg/kg Rb2 for 10 days had lower blood glucose level and higher insulin sensitivity compared with the control group [32]. More results from other studies demonstrated that Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days. Rb2 could reduce IR in mice administrated with 40 mg/kg Rb2 for 10 days.

**3.2. Cardioprotective effect of Ginsenoside Rb2**

**3.2.1. Treatment for MI/R injury**

Myocardial ischemia/reperfusion (MI/R) injury is an adverse cardiovascular outcome after myocardial ischemia, cardiac surgery or circulatory arrest, resulting in arrhythmia, cardiomyocyte apoptosis and heart hypofunction [41]. Oxidative stress and the accelerated reactive oxygen species (ROS) production play key roles in the progression of MI/R, causing direct cardiomyocyte damages, myocardial remodeling and heart failure [42,43]. In animal model of MI/R injury rats, Rb2 (10 and 20 mg/kg) enhanced the activities of antioxidant enzymes, including catalas (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX), in a dose-dependent manner and played a protection against ROS damages [44,45].

Oxidative stress and ROS were characterized by excessive inflammatory responses, which lead to necrosis and apoptosis of cardiomyocytes [47]. Treatment with Rb2 significantly reduced inflammatory cytokines levels (IL-1β, IL-6 and TNF-α) in the MI/R injury rats (P < 0.01) [48]. Further studies confirmed that sirtuin-1 (SIRT1) was a mediator to decrease oxidative stress, ROS and pro-inflammatory cytokines, and Rb2 could upregulate the expression of SIRT1 and play a protective role in the MI/R injury [48–50].

**3.2.2. Treatment for atherosclerosis**

Inflammatory response was important risk factors in the pathogenesis of atherosclerosis [51]. In LPS-treated HUVECs and THP-1 myocytes cell lines, treatment with Rb2 (20 μM) alleviated inflammatory responses by downregulating the phosphorylation of NF-κB and the release of TNF-α and MCP-1 in a dose-dependent manner [52]. However, ROS level had no change after the treatment with Rb2. This finding was linked with the upregulation mechanism of Rb2 on the expression of GP120/AMPK/HO-1 signaling in HUVECs. In another study, Rb2 showed a similar impact on inflammation by regulating GP120 signaling in LPS-stimulated mouse macrophage RAW264.7 cells [53].

The above results indicated Rb2 had good cardioprotective effects by inhibiting oxidative stress, ROS and inflammatory responses. Rb2 could be developed into a potent drug for heart diseases.
An in vivo and in vitro study reported anti-osteoporosis potency of Rb2. ROS and oxidative damage would inhibit osteoblast differentiation and enhance bone resorption, resulting in the progression of osteoporosis. In ovariectomized mice, Rb2 administration for 12 weeks partly inhibited serum oxidative damage and rescued anti-oxidant enzyme activities, such as malondialdehyde (MDA) and glutathione (GSH). Moreover, Rb2 improved trabecular micro-architecture and bone mass in mice [19]. In vitro, treatment of Rb2 (0.1–10 μM) dose-dependently protected osteoblastic MC3T3-E1 cells against osteoblast dysfunction and oxidative damage through reducing the level of ROS and bone-resorbing cytokines [19]. Bo et al. [54] found the anti-apoptotic effect of Rb2 on Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs), which had a direct inhibitory impact on osteoporosis. The molecular mechanism showed that Rb2 reversed Dex-induced apoptosis and improved the cell viability by activating the GPR120/Ras/Erk1/2 cascade in BMMSCS. Another study demonstrated the inhibitory effects of Rb2 on osteoclast differentiation and bone resorption activity. This mechanism was associated with blocking NF-kB and STAT3 signaling pathways [55]. In summary, Rb2 displayed protective effects against osteoporosis by regulating the differentiation of osteoblast and osteoclast, and it was a promising agent for the treatment of osteoporosis.

3.3. Anti-osteoporosis

3.4. Anti-cancer

The anti-carcinogenic properties of Rb2 on colorectal have been reported in several studies. The paper reported that the tumor growth and volume of mice were significantly inhibited in the Rb2 treatment group than the control group [57]. Intraportal administration of Rb2 (5 mg/kg) significantly suppressed the metastasis of colorectal cancer cells in a mouse model of metastasis (p < 0.05) [56]. Studies also determined the anti-tumor effects of Rb2 in the colorectal cancer cell lines HCT116, HT29 and SW620, inhibiting the growth, migration, invasion and wound healing of colorectal cancer cells [56,57]. The study found that Rb2 decreased the expression of Epithelial-mesenchymal transition (EMT) and cancer stem cells via the downregulation of EGFR/SOX2 and SIRT1 [57]. Another study verified the inhibitory mechanism of Rb2 against EMT through downregulating the TGF-β1/Smad signaling in vivo and in vitro.

In the research of anti-lung cancer, multiple administrations of Rb2 significantly inhibited the lung metastasis, produced by B16-BL6 cells, in a time-dependent manner in mice. The possible mechanism was partly due to the inhibition of tumor-associated angiogenesis by Rb2, and its underlying mechanism still needs to be investigated [58].

3.5. Anti-UV

Only a few studies have reported the anti-photoaging effect of Rb2. The ultraviolet (UV) could induce the production of ROS and disrupt the antioxidant ability of skin, and sequentially cause skin photaging and other skin diseases. Pretreatment with Rb2 obviously reduced the UV-B-induced ROS enhancement in a dose-dependent manner in human dermal keratinocytes and bone mass in mice [19]. In vitro, treatment of Rb2 (0.1–10 μM) dose-dependently protected osteoblastic MC3T3-E1 cells against osteoblast dysfunction and oxidative damage through reducing the level of ROS and bone-resorbing cytokines [19]. Bo et al. [54] found the anti-apoptotic effect of Rb2 on Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs), which had a direct inhibitory impact on osteoporosis. The molecular mechanism showed that Rb2 reversed Dex-induced apoptosis and improved the cell viability by activating the GPR120/Ras/Erk1/2 cascade in BMMSCS. Another study demonstrated the inhibitory effects of Rb2 on osteoclast differentiation and bone resorption activity. This mechanism was associated with blocking NF-kB and STAT3 signaling pathways [55]. In summary, Rb2 displayed protective effects against osteoporosis by regulating the differentiation of osteoblast and osteoclast, and it was a promising agent for the treatment of osteoporosis.
neuroprotective effects of Rb2 were thought to be due to the up-regulation of antiapoptotic Bcl-2 and downregulation of pro-apoptotic Bax and MAPKs.

3.7. Anti-virus

It is reported that ginseng and ginsenosides have preventive effects on virus infection, such as H1N1, H1N2, murine norovirus and feline calcivirus. The protective abilities of ginsenosides (Rb1, Rb2, Rd, Re, Ro and Rg2) against the lethal infection of haemagglutinating virus of Japan (HVJ) in mice were studied, and pretreatment of Rb2 showed the highest potency with a 71.4% survival rate [65]. The protective mechanism of Rb2 was involved in the enhancement of mucosal immunity and the suppression of HVJ virus growth in HVJ-infectious mice. In the newborn mice of rotavirus infection, pretreatment of Rb2 reduced virus titers and RV-induced diarrhea in a dose-dependent and time-dependent manner [66]. These results meant that Rb2 was a promising candidate as an antiviral reagent to prevent infection.

4. Conclusion

The review focused on the current content concerning the source, pharmacokinetics and pharmacology of Rb2. Accumulating evidence has proved beneficial effects of Rb2 on many diseases in vitro and animal models (Fig. 2), including anti-diabetes, anti-obesity, anti-inflammation, anti-oxidation, anti-virus, anti-tumor and effects on the cardiovascular system. The diverse bioactivities were attributed to the regulation of Rb2 on the signaling pathways and molecules, such as AKT/SHP, MAPK, EGFR/SOX2, TGF-β1/Smad, SIRT1, GPR120/AMPK/HO-1 and NF-κB. In particular, the paper outlined the anti-diabetic potency of Rb2 through multi-effects, multi-targets and multi-pathways, which provided a potential lead drug for the treatment of diabetes and its complications.

The PK profiles of Rb2 exhibit poor oral absorption and bioavailability that restricts its efficacy and clinical use. More strategies for overcoming its poor absorption are urgent, such as new drug delivery systems, chemical modification and so on. In the aspect of pharmacology, some specific mechanisms have not yet been fully elucidated. For example, Rb2 inhibited the metastasis of tumor in lung cancer, but its regulatory mechanism is not clear. In anti-UV, neuroprotection and anti-virus, there is a lack of more deep and systemic investigations. The currently available results are mainly collected from in vitro cell culture experiments and in vivo rodent models, and further investigations should concentrate on how to do more research in clinical.

In this paper, we have tried to elucidate the pharmacokinetic and pharmacological profiles of Rb2, and these findings could provide a reference for the development of Rb2 as a promising drug.

Declaration of competing interest

The author declares no conflicts of interest.
ACKNOWLEDGMENTS

This work was supported by the Project of Shandong Provincial Medical Association Foundation (Grant No. YXH2020X050), Shandong Provincial Natural Science Foundation, China (ZR2020MH370), the Project of Shandong Province Key Research and Development Program (Grant No. 2017YS0030), and Jinan Science and Technology Project (Grant No. 201303055), Shandong Medical and Health Science and Technology Development Project (Grant No. 2017WSB13007).

References

[1] Yun T-K. Panax ginseng—a non-organ-specific cancer preventive? Lancet Oncol 2001;2(1):49–55.
[2] Ramaswami R, Stebbing J. Ginseng: panacea among herbal remedies? Lancet Oncol 2013;14(3):395–6.
[3] Sharma A, Lee HJ. Ginsenoside compound K: insights into recent studies on pharmacokinetics and health-promoting activities. Biomolecules 2020;10(7).
[4] Piao X, Zhang H, Kang JP, Yang DU, Li Y, Pang S, et al. Advances in Saponin Diversity of Panax ginseng. Molecules. 2020;25(15).
[5] Lee JW, Choi BR, Kim YC, Choi DJ, Lee YS, Kim GS, et al. Comprehensive profiling and quantification of ginsenosides in the root, stem, leaf, and berry of Panax ginseng by UPLC-QTOF/MS. Molecules 2017;22(12).
[6] Lu QZ. Chemical insights into ginseng as a resource for natural antioxidants. Chem Rev 2012;112(3):3293–55.
[7] akino mky. Studies on absorption. distribution excretion and metabolism of ginseng saponins. comparison of decomposition modes of ginsenoside rb1 and rb2 in the digestive tract of rats. 1991.
[8] Zhao J, Su C, Yang C, Liu M, Tang L, Su W, et al. Determination of ginsenosides Rb2, Rb3, and Rd in rat plasma by a rapid and sensitive liquid chromatography tandem mass spectrometry method: application in a pharmacokinetic study. J Pharmaceut Biomed Anal 2012;65:94–100.
[9] Wang W, Ha L, Li X, Zheng W, Yang E. Pharmacokinetic and metabolism study of ginsenoside Rb2 in rat by liquid chromatography combined with electrospay ionization tandem mass spectrometry. Biomed Chromatogr : BMC Biomed Chromatogr 2011;35(11):e5191.
[10] Zhao J, Yang CH, Hu M, Liu QZ. [Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer]. Nan fang yi ke da xue xue bao – Journal of Southern Medical University 2009;29(12):2387–90.
[11] Tawab MA, Bahr U, Karas M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos: the biological fate of chemicals 2003;31(8):1065–71.
[12] Chi H, Kim DH, Ji GE. Transformation of ginsenosides Rb2 and Rc from Panax ginseng saponins. comparison of decomposition modes of ginsenoside rb1 and rb2 in the digestive tract of rats. 1991.
[13] Tian XP, Yin YY, Li X. Effects and mechanisms of Acremoniumterricola mill-eretal mycelium on liver function. Oxidative Medicine and Cellular Longevity 2016;2016:1
[14] Liu X, Jiang Y, Fu W, Yu X, Sui D. Combination of the ginsenosides Rb3 and Rb2 for the treatment of obesity. Eur J Drug Metab Pharmacokinet 2017;42(4):545–54.
[15] Liang Y, Zhou Y, Zhang J, Rao T, Zhou L, Xing R, et al. Pharmacokinetic compatibility of ginsenosides and Schisandra Lignans in Shengmai-san: from the perspective of p-glycoprotein. PLoS One 2014;9(6):e87817.
[16] Qiu S, Yang W-Z, Yao C-L, Shi X-J, Li J-Y, Lou Y, et al. Malonylginsenosides with potential antidiabetic activities from the flower buds of Panax ginseng. J Nat Prod 2017;80(4):899–905.
[17] Jeon H-J, Lee S, Lee W, Jin S, Kwon M, Shin CH, et al. Herb–drug interaction of red ginseng extract and ginsenoside Rb2 with valsartan in rats. Molecules 2020;25(3).
[18] Jeon JT, Jung NW, Lee H-J. Ginsenoside Rb1 reduces cholesterol and triacylglycerol levels in 3T3-L1 adipocytes cultured under high cholesterol or fatty acids conditions. BMB reports 2009;42(4):194–9.
[19] Lim G, Lee H, Kim E-J, Noh Y-H, Ro Y, Koo J-H. Ginsenoside Rb2 upregulates the low density lipoprotein receptor gene expression through the activation of the sterol regulated element binding protein maturation in HepG2 cells. J Ginseng Res 2005;29.
[20] Muller AL, Hryshko LV, Dhalla NS. Extracellular and intracellular proteases in cardiac dysfunction due to ischemia–reperfusion injury. Int J Cardiol 2013;164(1):39–47.
[21] Yu L, Li Q, Yu B, Yang Y, Jin Z, Duan W, et al. Berberine attenuates myocardial ischemia/reperfusion injury by reducing oxidative stress and inflammation response. Oxidative Medicine and Cellular Longevity 2016;2016:1896002.
[22] Yao W, Wang X, Xiao K. Protective effect of berberine against cardiac ischemia/reperfusion injury by inhibiting apoptosis through the activation of Smad7. Mol Cell Probes 2018;38:38–44.
[23] Tian XP, Yin Y, Li X. Effects and mechanisms of Acromenunticerricola milleretum on liver fibrosis induced by carbon tetrachloride in rats. Am J Chin Med 2011;39(3):537–50.
[24] Fu W, Yu X, Liu Z, Sun F, Wang Y, Zhang Y, et al. Protective effects of ginsenoside Rb2 on myocardial ischemia in vivo and in vitro. 2016;9:9843–55.
[25] Liu X, Jiang Y, Fu W, Yu X, Sui D. Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats. Int J Mol Med 2020;45(2):519–31.
[26] Zorov DB, Filburn CR, Kloz LT, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000;192(7):1001–14.
[27] Xue Y, Fu W, Liu Y, Yu P, Sun M, Li X, et al. Ginsenoside Rb2 alleviates myocardia ischemia/reperfusion injury in rats through SIRT1 activation. J Inflamm (Lond) 2020;17:81.
[28] Palmirotta R, Cives M, Della-Morte D, Capuani B, Lauro D, Guardagni F, et al. Sirtuins and cancer: role in the epithelial-mesenchymal transition. Oxid Med Cell Longev 2016;2016:3013459.
[29] Wang X, Yang L, Chen Y, Zhang X. Screening SIRT1 activators from medicinal plants as bioactive compounds against oxidative damage in mitochondrial function. Oxidative Medicine and Cellular Longevity 2016;1:1–9.
[30] Conti P, Shakk-Dastagirisaeb Y. Atherosclerosis: a chronic inflammatory disease mediated by mast cells. Curr Eur J Immunol 2015;40(3):380–6.
Yoo YC, Lee J, Park SR, Nam KY, Cho YH, Choi JE. Protective effect of Ginsenoside Rb2 ameliorates LPS-induced inflammation and ER stress in HUVeCs and THP-1 cells via the AMPK-mediated pathway. Am J Chin Med 2020;48(4):967–85.

Huang Q, Wang T, Wang H-y. Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264.7 macrophages by upregulating GPR120 expression. Acta Pharmacol Sin 2016;38(2):192–200.

Gao B, Huang Q, Je Q, Zhang H-Y, Wang L, Guo Y-S, et al. Ginsenoside-Rb2 inhibits dexamethasone-induced apoptosis through promotion of GPR120 induction in bone marrow-derived mesenchymal stem cells. Stem Cell Dev 2015;24(6):781–90.

Cong F, Liu J, Wang C, Yuan Z, Bi L, Liang J, et al. Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β-Smad signaling. Phytomedicine 2019;56:126–35.

Phi LTH, Wijaya YT, Sari IN, Yang Y-G, Lee YK, Kwon HY. The anti-metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2-dependent manner. Cancer Medicine 2018;7(11):5621–31.

Sato K, Mochizuki M, Saiki I, Yoo VC, Samukawa K, Azuma I. Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biological & pharmaceutical bulletin 1994;17(5):635–9.

Oh S-J, Kim K, Lim C-J. Suppressive properties of ginsenoside Rb2, a protopanaxadiol-type ginseng saponin, on reactive oxygen species and matrix metalloproteinase-2 in UV-B-irradiated human dermal keratinocytes. Bioch Biotechnol Biochem 2015;79(7):1075–81.

Oh S-J, Kim K, Lim C-J. Ginsenoside Rb2 attenuates UV-B radiation-induced reactive oxygen species and matrix metalloproteinase-2 through upregulation of antioxidant components in human dermal fibroblasts. Pharmacology 2015;96(1–2):32–40.

Kang KS, Kim HY, Baek SH, Yoo HH, Park JH, Yokozawa T. Study on the hydroxyl radical scavenging activity changes of ginseng and ginsenoside-Rb2 by heat processing. Biopharm Bull 2007;30(4):724–8.

Dong X, Zheng L, Lu S, Yang Y. Neuroprotective effects of pretreatment of ginsenoside Rb1 on severe cerebral ischemia-induced injuries in aged mice: involvement of anti-oxidant signaling. Geriatr Gerontol Int 2017;17(2):338–45.

Wang L, Zhao H, Zhai ZZ, Qu LX. Protective effect and mechanism of ginsenoside Rg1 in cerebral ischaemia-reperfusion injury in mice. Biomedicine & pharmacotherapy Biomedicine & pharmacotherapy 2018;99:876–82.

Kim DH, Kim DW, Jung BH, Lee JH, Lee H, Hwang GS, et al. Ginsenoside Rb2 suppresses the glutamate-mediated oxidative stress and neuronal cell death in HT22 cells. J Ginseng Res 2019;43(2):326–34.

Yoo YC, Lee J, Park SR, Nam KY, Cho YH, Choi JE. Protective effect of ginsenoside-Rb2 from Korean red ginseng on the lethal infection of haemagglutinating virus of Japan in mice. J Ginseng Res 2013;37(1):80–6.

Yang H, Oh K-H, Kim HJ, Cho YH, Yoo YC. Ginsenoside-Rb2 and 20(S)-Ginsenoside-Rg3 from Korean red ginseng prevent rotavirus infection in newborn mice. J Microbiol Biotechnol 2018;28(3):391–6.

Xie H, Wang D, Zhang W, Yan X, Zhao Y. Comparative pharmacokinetic studies of four ginsenosides in rat plasma by UPLC–MS/MS after oral administration of Panax quinquefolius-ocular ginsenosides and Panax quinquefolius extracts. Journal of Analytical Methods in Chemistry 2019;2019:1–13.

Ouyang H, Liu F, Tang Z, Chen X, Bo F, Liu H, et al. A validated LC-MS/MS method for simultaneous determination of six aconitum alkaloids and seven ginsenosides in rat plasma and application to pharmacokinetics of shen-fu prescription. Evid base Compl Alternative Med 2018;2018:1–12.

Han SY, Baeg MG, Choi YH. Stereoselective and simultaneous analysis of ginsenosides from ginseng berry extract in rat plasma by UPLC-MS/MS: application to a pharmacokinetic study of ginseng berry extract. Molecules 2018;23(7).

Zhou Q-L, Zhu D-N, Yang Y-F, Xu W, Yang X-W. Simultaneous quantification of twenty-one ginsenosides and their three aglycones in rat plasma by a developed UPLC–MS/MS assay: application to a pharmacokinetic study of red ginseng. J Pharmaceut Biomed Anal 2017;137:1–12.

Li Z, Zhang R, Wang X, Hu X, Chen Y, Liu Q. Simultaneous determination of seven ginsenosides in rat plasma by high-performance liquid chromatography coupled to time-of-flight mass spectrometry: application to pharmacokinetics of Shengfu injection. Biomed Chromatogr 2015;29(2):167–75.

Jin Y, Tian T, Ma Y, Xu H, Du Y. Simultaneous determination of ginsenoside Rb1, naringin, ginsenoside Rb2 and oridonin in rat plasma by LC–MS/MS and its application to a pharmacokinetic study after oral administration of Weifuchun tablet. J Chromatogr B 2015;1000:112–9.

Zhou D, Tong L, Wan M, Wang G, Ye Z, Wang Z, et al. An LC-MS method for simultaneous determination of nine ginsenosides in rat plasma and its application in pharmacokinetic study. Biomed Chromatogr 2011;25(6):720–6.

Chen J, Li M, Qu D, Sun Y. Neuroprotective effects of red ginseng saponins in scopamine-treated rats and activity screening based on pharmacokinetics. Molecules 2019;24(11).

Zhi H, Deng Y, Yan B, Li Z, Han S, Zhang Y, et al. Study on the herb-herb interaction of Danqi Tongmai Tablet based on the pharmacokinetics of twelve notoginsenosides in acute myocardial ischemia and sham rats. J Pharmaceut Biomed Anal 2019;166:52–65.

Zheng H-r, Chui Y, Zhou D-z, Ju A-c, Li W, Li X, et al. Integrated pharmacokinetics of ginsenosides after intravenous administration of YiQiFuMai powder in rats with chronic heart failure by UFLC–MS/MS. J Chromatogr B 2018;1072:282–9.

Zhang F, Zhang Y, Li X, Zhang S, Zhu M, Du W, et al. Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association. Phytomedicine 2018;44:220–30.

Yi Q, Cui Li-Qiang, Xin Y, et al. Simultaneous determination and pharmacokinetics of eight ginsenosides by UFLC–MS after intravenously infusion of shenfu injection in dogs. Yi Q, Cui Li-Qiang, Xin Y, 2017. *.

Yu1 Jian, Gu1 Li-Qiang, Xin1 Yan-Fei, Gao1 Hai-Yan, Xu1 Xiao-Zhen, Liao1 He-Liang, et al. Research on Q-markers of Shenfu injection. J Ginseng Res 46 (2022) 206–213.